Clinical Trial Update: Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of sorafenib and erlotinib in patients with stage IIIB or stage IV non-small cell lung cancer that has not r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Nexavar (Sorafenib)
• Tarceva (erlotinib)

Snippet

Sponsor: Yonsei University | Conditions: Lung Cancer | Phase 2 | Status: UNKNOWN